
Jan 12 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O:
MIRUM PHARMACEUTICALS ANNOUNCES PRELIMINARY UNAUDITED 2025 RESULTS, DEMONSTRATING STRONG COMMERCIAL GROWTH AND PIPELINE MOMENTUM
MIRUM PHARMACEUTICALS INC - PRELIM 2025 NET PRODUCT SALES OF APPROXIMATELY $520 MILLION EXCEED UPPER END OF GUIDANCE
MIRUM PHARMACEUTICALS INC - 2026 EXPECTED GLOBAL NET PRODUCT SALES OF $630 MILLION TO $650 MILLION
MIRUM PHARMACEUTICALS INC - VOLIXIBAT VISTAS STUDY IN PRIMARY SCLEROSING CHOLANGITIS (PSC) TOPLINE DATA EXPECTED Q2 2026
MIRUM PHARMACEUTICALS INC - LIVMARLI EXPAND STUDY IN ADDITIONAL CHOLESTATIC PRURITUS SETTINGS TIMING ACCELERATED; TOPLINE DATA NOW EXPECTED Q4 2026
MIRUM PHARMACEUTICALS - BLUEJAY THERAPEUTICS' AZURE-1 STUDY IN HDV INTERIM DATA EXPECTED IN Q2 2026, TOPLINE PHASE 3 DATA EXPECTED IN H2 2026